Сахарный диабет (Oct 2014)

National advisory board on diabetes mellitus: unsolved issues and new opportunities for diabetes treatment

  • Gagik Radikovich Galstyan

DOI
https://doi.org/10.14341/DM20143129-133
Journal volume & issue
Vol. 17, no. 3
pp. 129 – 133

Abstract

Read online

In June 2014, the national experts on diabetes mellitus discussed the opportunities to improve the efficacy and outcomes of diabetes treatment using the strategy of patient-oriented care in diabetes. Insulin degludec (Tresiba?) is a new basal ultra-long-acting insulin analogue with a flat, stable glucose-lowering profile, ultra-long duration of action (>=42 h) and less within-patient day-to-day variability in glucose-lowering effect compared with currently available basal insulins. In the clinical trial programme, insulin degludec showed a similar glycaemic control compared with insulin glargine using the same insulin dose, but with a lower risk of hypoglycaemia and a greater flexibility in the time of dosing on a daily basis, when needed. Thus, the use of insulin degludec in routine clinical practice provides an effective and improved treatment for type 1 and 2 diabetes. The simple algorithm titration of insulin degludec offers the opportunity to personalise treatment regimens according to the needs of each patient.

Keywords